Loading...

Neurocrine Biosciences, Inc.

NBIXNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$124.61
$0.09(0.07%)

Neurocrine Biosciences, Inc. NBIX Peers

See (NBIX) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NBIX$124.61+0.07%12.3B42.24$2.95N/A
ZTS$168.68+0.05%75.1B30.28$5.57+1.10%
HLN$11.11+1.60%50.2B25.83$0.43+1.51%
TAK$15.00-0.20%47.2B65.22$0.23+3.94%
TEVA$17.24-1.63%19.7B-14.99-$1.15N/A
ITCI$131.87N/A14B-180.64-$0.73N/A
RDY$15.53+5.29%12.9B19.66$0.79+0.62%
CTLT$63.48N/A11.5B-27.84-$2.28N/A
VTRS$8.46-1.51%9.9B-2.66-$3.18+5.67%
RGC$617.52-2.00%8B-2058.40-$0.30N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NBIX vs ZTS Comparison

NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 12.3B. In comparison, ZTS has a market cap of 75.1B. Regarding current trading prices, NBIX is priced at $124.61, while ZTS trades at $168.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 42.24, whereas ZTS's P/E ratio is 30.28. In terms of profitability, NBIX's ROE is +0.12%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, NBIX is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.

Stock Price Comparison

Loading...

Frequently Asked Questions